Samsung BioLogics seals coveted $2bn IPO

korea px230
By Jonathan Breen
28 Oct 2016

Samsung BioLogics Co has priced its IPO at the top on the back of a surge in chunky orders, raising W2.25tr ($2.0bn) in South Korea's largest float since 2010.

The drug manufacturing arm of Korean conglomerate Samsung Group started the deal on a strong footing thanks to plenty of investor interest ahead of launch. And after kicking off bookbuilding, demand flew in, with orders coming in size.

“The deal could have been placed with just two investors,” ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial